UNRESECTABLE HEPATOCELLULAR CARCINOMA
Clinical trials for UNRESECTABLE HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost immune attack on untreatable liver tumors
Disease control Recruiting nowThis study is for people with advanced liver cancer that cannot be removed by surgery. It tests whether injecting a patient's own specially trained immune cells (dendritic cells) into the tumor, along with immunotherapy drugs, after high-dose radiation is safe and can help contro…
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 00:00 UTC
-
New combo therapy aims to stop liver cancer in its tracks
Disease control Recruiting nowThis study tests whether combining the drug regorafenib with a type of internal radiation (Y-90) can control advanced liver cancer that cannot be removed by surgery. About 30 adults with unresectable hepatocellular carcinoma will receive the combination. The goal is to see how ma…
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated May 16, 2026 23:59 UTC
-
Liver cancer hope: combo therapy may boost survival after first treatment fails
Disease control Recruiting nowThis study is for people with advanced liver cancer that cannot be removed by surgery and has gotten worse after initial treatment with atezolizumab plus bevacizumab. Researchers want to see if adding another immunotherapy drug (atezolizumab) to a standard targeted therapy pill (…
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 16, 2026 23:56 UTC
-
New combo therapy offers hope for patients with inoperable liver cancer
Disease control Recruiting nowThis study tests whether adding immunotherapy (camrelizumab) and a targeted drug (apatinib) to a standard liver cancer treatment called TACE can help people with advanced liver cancer live longer without their cancer growing. About 101 adults with liver cancer that cannot be surg…
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE3 • Sponsor: Guohui Xu • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
New quadruple therapy targets tough liver tumors
Disease control Recruiting nowThis study tests a four-part treatment for people with advanced liver cancer that cannot be removed by surgery. It combines internal radiation (Y90) with three drugs (nivolumab, ipilimumab, lenvatinib) to shrink tumors and extend life. The trial enrolls 33 adults and focuses on s…
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New combo attack on liver cancer shows early promise
Disease control Recruiting nowThis early-stage study tests whether combining two drugs (atezolizumab and bevacizumab) with targeted radiation (SBRT) is safe for people with liver cancer that cannot be removed by surgery. About 20 participants will receive the combination to check for side effects and see how …
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for liver cancer: pfizer launches drug combo trial
Disease control Recruiting nowThis study tests a new medicine called PF-08634404, given alone or with another drug (ipilimumab), for adults with advanced liver cancer that cannot be removed by surgery. The goal is to check safety and see if the treatment shrinks tumors. About 138 participants will receive the…
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New combo therapy aims to turn inoperable liver cancer into operable disease
Disease control Recruiting nowThis pilot study tests a new approach for people with inoperable liver cancer. The goal is to shrink tumors using a combination of immunotherapy and targeted radiation, so that surgery to remove the cancer becomes possible. The study will enroll 30 participants and measure how ma…
Matched conditions: UNRESECTABLE HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated May 11, 2026 20:46 UTC